AZNAstraZenecaSigning up patients
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Gastric Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 163 (planned)
- Started
- Jan 16, 2023
- Main results expected
- Nov 30, 2027
- Fully finished
- May 31, 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
ORR (per RECIST 1.1 as assessed by Investigator)
Measured over: Through substudy completion, an average of 2 years
PFS6 (per RECIST 1.1 as assessed by Investigator)
Measured over: Through substudy completion, an average of 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05702229 · record last updated 2026-05-14 · checked 2026-11-09 15:47 UTC